The Largest Application Area in Diagnostics Has No Leader

No vendor holds twelve per cent of the largest application area in diagnostics

Infectious disease diagnostics is a USD 30,150 million market in 2025 on our construction — 27.92 per cent of the entire in vitro diagnostics base. The largest single vendor pool in it, Abbott’s, is USD 3,577 million, or 11.86 per cent. The top five pools together reach 42.27 per cent.

Set that against the disciplines underneath. Sysmex holds 18.3 per cent of haematology. bioMérieux holds 17.1 per cent of microbiology. Two disciplines, each with a vendor large enough to be the reference for price, and a field nearly three times their combined size in which no one above twelve per cent exists.

That is not a rounding effect and it is not a market in transition toward consolidation. It is the perimeter, and once you see it, most of the pricing behaviour in this field follows from it.

The perimeter is a clinical question, so the competitive set changes test by test

Our report on this field defines it by the question a clinician asks — is there a pathogen, and which one — rather than by instrument, technique or sample type. That decision has a consequence the industry rarely states plainly: the competitor for a molecular syndromic panel is a blood culture, a lateral flow antigen test, a laboratory-developed assay and sometimes no test at all. Each of those has a different manufacturer, a different cost structure and a different code.

So the field’s seven segments do not share a supplier base. Laboratory microbiology (USD 8,830 million, 5.14 per cent CAGR) is a culture business contested by bioMérieux, BD and Danaher. Molecular syndromic and multiplex panels (6,300 million, 6.46 per cent) are contested by bioMérieux, Roche, Qiagen, Abbott and a set of regional assay houses. Serology and immunoassay pathogen detection (5,900 million, 3.21 per cent) sits inside an installed base that Abbott, Roche and Siemens built for other reasons entirely. Rapid antigen and point-of-care (4,300 million, 3.12 per cent) belongs to Abbott, QuidelOrtho and a long tail. Viral load and treatment monitoring (2,900 million, 4.10 per cent) is Roche and Cepheid. Blood donor and transplant screening (1,500 million, 4.61 per cent) is mostly Grifols, Roche and Abbott. Metagenomic identification (420 million, 14.02 per cent) is a research-grade business only now acquiring a clinical price.

No company is large in more than three of those. Concentration measured across the field therefore cannot be high, because the field is a portfolio of adjacent contests rather than one contest. This is the opposite of haematology, where a single installed base of analysers and a single reagent stream produce a 18.3 per cent leader almost mechanically.

What the absence of a leader does to price

In a discipline with a leader, the leader has a reason to defend the price of its code, because the code is its annuity. In a field with no leader, nobody’s annuity is at stake, and nobody spends political capital on the fee schedule.

The arithmetic carries the effect. Across this field, revenue per test falls from USD 5.025 to USD 4.787 between 2025 and 2033 — a 4.7 per cent decline over eight years, roughly 0.61 per cent a year. Decomposed, the constant-menu price effect is −2.10 per cent a year and the mix effect is +1.49 per cent a year. Volume runs at 5.49 per cent against revenue at 4.85 per cent: more tests, less money each, and growth that has to be bought with a richer menu rather than earned with a bigger one.

The mix engine is panelisation, and it is finite. Once syndromic and metagenomic work reaches roughly a quarter to a quarter and a half of the base — they are 22.29 per cent today, producing 35.13 per cent of the increment — the mix effect converges toward zero and growth converges on three to three and a half per cent. A fragmented field cannot accelerate its way out of that, because no participant has the share to reprice the category.

The residual is a disclosure fact, not a hidden vendor

Thirteen vendor pools carry 59.65 per cent of the USD 30,150 million. USD 12,166 million — 40.35 per cent — is unattributed, the largest residual in this cluster of reports.

That figure is often misread as a missing company. It is not. Hard disclosure in this field is 22.42 per cent, and it comes from three companies: Abbott’s three reported lines, bioMérieux’s two application lines, and Qiagen’s diagnostic solutions line. ‘Disclosed’ means a usable reported line, not a pure one — Abbott’s split from segment to field is our allocation, and it is labelled as ours in the report. Ten of the thirteen pools rest on estimates. The residual is where the companies that do not publish a pathogen-testing line live, and it is stated as a limit of the construction rather than absorbed into a plausible name.

The reporting structure is itself part of the fragmentation story. A field whose participants do not report it as a field will not produce a share leader in anyone’s data, including a regulator’s.

Where consolidation is actually coming from

Two moves in the last twelve months describe the direction. BD is combining Diagnostic Solutions with Waters around the end of the first quarter of calendar 2026, leaving ‘New BD’ as a medtech company — the leading blood-culture franchise is moving into an analytical-instruments perimeter, which is a statement about which multiple its growth rate supports. And Roche, which owns the central-lab channel, has been building into Abbott’s channel with 53 new tests including a CLIA-waived 15-minute Bordetella PCR.

Neither is consolidation of the field. Both are reclassification: participants deciding which adjacent business their revenue can be valued inside. That is what a fragmented market looks like when it matures — not a scramble for share, but an exit from the perimeter.

What this analysis does not claim

The volume series behind the revenue-per-test finding is modelled from the revenue construction, not disclosed by any participant. The direction of the finding follows from the mix arithmetic and is robust; the absolute level of revenue per test is a construct, and we say so in the report rather than presenting it as observed data.

On method: the mechanisms here — why panels displace cultures, why a waived test moves a price from a lab menu to a payer schedule, why tender cycles set the discount before the volume arrives — come from 38 depth interviews across 11 markets, 24 open-ended interviews conducted around tender cycles, a 171-respondent survey and four conferences. That programme is used to establish how the market works. It never carries a number; every figure in this piece is from a filing, a regulator or our own model.

The full segment, attribution, product Split and regional tables are in Global Infectious Disease Diagnostics Market, 2026–2033. The discipline reports this field sits above are microbiology, immunoassay, clinical chemistry and haematology and coagulation, with the revenue-model spine in IVD reagents and consumables.

Companion reading

Three other pieces sit on the same construction. The Pandemic Built the Point-of-Care Channel and the Channel Is Now Repricing is the concentration finding read at the channel level: Abbott’s COVID sales fall 60.2 per cent and point-of-care becomes the field’s slowest segment at 3.12 per cent. The Two Families Infectious Disease Tests Are Paid In Were Both Cut explains why a field with no price leader also cannot defend a code, and quantifies the exposure at 61.19 per cent of the base. The Largest Risk to Infectious Disease Diagnostics Is a Budget Line, Not a Competitor completes the picture with the one variable no vendor controls.